Psychiatric comorbidities in epilepsy are significantly more prevalent among individuals with vs those without the condition, according to study findings published in JAMA Neurology.
A team of researchers conducted a systematic review and meta-analysis of epidemiological studies to estimate the prevalence of common psychiatric disorders in persons with epilepsy. Articles were included in the analysis if they reported original data, investigated 1 of 15 predetermined psychiatric disorders, used a validated symptom measure or other validated data collection measures, included controls, and reported the prevalence of a single psychiatric disorder. Studies were excluded if they contained non–peer-reviewed data or involved studies of less than 30 people.
Odds ratios (ORs) were calculated using the Mantel-Haenszel method; the Higgins I2 test and Cochran Q statistic were employed for statistical analysis.
A total of 27 studies met eligibility criteria; the meta-analysis included 565,443 persons with and 13,434,08 persons without epilepsy. Pooled analysis of the 15 studies that reported a significantly higher prevalence of anxiety disorders in individuals with vs those without epilepsy (8.4% vs 5.7%; OR, 2.11; 95% CI, 1.73-2.58; P <.001). Analysis of individual anxiety disorders showed a significantly higher prevalence in generalized anxiety disorder and specific phobia, but not for social phobia or agoraphobia.
Pooled analysis of the 16 studies involving depression showed a significantly higher prevalence in persons with vs those without epilepsy (13.7% vs 9.3%; OR, 2.45; 95% CI, 1.94-2.09; P <.001). Pooled analysis of 4 studies of bipolar disorder showed a significantly higher prevalence for persons with vs those without epilepsy (1.2% vs 1.1%; OR, 3.12; 95% CI, 2.23-4.46; P <.001). Significant moderators to the overall effect included age 19 years older, diagnosis method for psychiatric comorbidity, diagnosis criteria for psychiatric comorbidity, and diagnosis method for epilepsy.
A significantly greater prevalence was also observed in persons with vs those without epilepsy for suicidal ideation (20.0% vs 11.7%; OR, 2.25; 95% CI, 1.75-2.88; P <.001), but not for suicide attempt (3.2% vs 0.6%; OR, 3.17; 95% CI, 0.49-20.46; P =.23).
The following conditions were more prevalent in persons with vs those without epilepsy:
- any psychotic disorder (14.8% vs 6.3%; OR, 3.98; 95% CI, 2.57-6.15; P <.001),
- schizophrenia (3.3% vs 0.9%; OR, 3.72; 95% CI, 2.44-5.67; P <.001),
- obsessive-compulsive disorder (OCD; 0.4% vs 0.1%; OR, 2.71; 95% CI, 1.76-4.15; P <.001),
- eating disorder (1.2% vs 0.7%; OR, 1.87; 95% CI, 1.73-2.01; P <.001), and
- post-traumatic stress disorder (PTSD; 5.6% vs 3.7%; OR, 1.76; 95% CI, 1.14-2.73; P =.01).
In addition, a significantly greater prevalence was observed in persons with vs those without epilepsy in the following disorders:
- alcohol misuse (6.8% vs 2.6%; OR, 3.64; 95% CI, 2.27-5.83; P <.001),
- alcohol dependence (3.3% vs 1.1%; OR, 4.94; 95% CI, 3.50-6.96; P <.001),
- substance use disorder (6.4% vs 5.2%; OR, 2.75; 95% CI, 1.61-4.72; P <.001),
- autism spectrum disorder (10.9% vs 1.0%; OR, 10.67; 95% CI, 6.35-17.91; P <.001), and
- attention-deficit/hyperactivity disorder (13.0% vs 3.4%; OR, 3.93; 95% CI, 3.80-4.08; P <.001)
No publication bias was observed in any of the meta-analyses. Study limitations included heterogeneity and the use of self-rating psychiatric instruments. “These findings show the high burden of psychiatric comorbidities in [persons with epilepsy]. The findings suggest that the training curriculum for epilepsy care should incorporate validated psychiatric screening tools,” the researchers concluded.
One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
References:
Kwon C-S, Rafati A, Ottman R, et al. Psychiatric comorbidities in persons with epilepsy compared with persons without epilepsy a systematic review and meta-analysis. JAMA Neurol. Published online November 25, 2024. doi: 10.1001/jamaneurol.2024.3976